This Plain Language Summary of Publication article (PLSP) from Future Oncology compared sacituzumab govitecan (TRODELVY®) with standard docetaxel chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had progressed after receiving platinum-based chemotherapy and immunotherapy. The research addresses an important clinical need, as treatment options for progressive NSCLC are limited and current alternatives offer poor survival outcomes with significant side effects.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study’ and was published in the Journal of Clinical Oncology.

Visit ASCO publications using the link to read the original article.